Abstract
We already discussed in another paper in this Volume the rational experimental and clinical basis of specific and nonspecific immunotherapy [15]. We have compared the respective value of BCG and that of agents making up the second generation of systemic adjuvants of immunity including Corynebacterium parvum, levamisole, synthetic polynucleotides, and polysaccharides such as krestin, etc. All these adjuvants have been the object of intensive studies on their mode of action, [6, 12] and they have been used in clinical trials of cancer immunotherapy [3, 12]. We underlined that, despite their unquestionable antitumoral activity, these agents in some cases may exert deleterious actions. Side-effects due to toxicity are often not negligible. Overall, many adjuvants may induce suppressor cells thought to play a role in tumor enhancement.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Reference
Bicker, O., Ziegler, B. E., Hebold, G.: 2-[2-cyanaziridinyl-(1)-]-2-[-2-carbamocyl aziridinyl-(1)]-propane BM 12 531. A new substance with immune stimulating action. I.R.C.S. Med. Sci. 5, 299 (1977).
Bicker, U., Hebold, G., Ziegler, A. E., Maus, W.: Animal experiments on the compensation of the immunosuppressive action of cyclophosphamide by 2-[-2-cyanaziridinyl-(1)-]-2-[-2-carbamocyl aziridinyl-(1)-]-propane BM 12 531. (in press) (1978).
Bonadonna, G., Mathé, G., Salmon, S. E. (eds.): Adjuvant therapies and markers of post-surgical minimal residual disease I. Berlin, Heidelberg, New York: Springer 1979.
Bruley-Rosset, M., Florentin, I., Kiger, N., Goldstein, A., Mathé, G.: Prevention of aged-induced immunodepression in mice by chronic treatment with thymosin and systemic adjuvants of immunity. Cancer Immunol. Immunother. (in press) (1978).
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., Williamson, B.: An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72, 3666 (1975).
Chirigos, M. A. (ed.): Immune modulation and control of neoplasia by adjuvant therapy. Cancer Treat. Rep. (in press) (1978).
Chretien, P.: The effects of thymosin in vitro on lymphocytes from cancer patients responding to thymosin immunotherapy. In: Human lymphocyte differentiation, its application to human cancer. Serrou, B., Rosenfeld, C. (eds.), Vol. 1. Amsterdam: Elsevier North-Holland (1978) (in press).
Diluzio, N.: An overview of glucan activity. In: Immune modulation and control of neoplasia by adjuvant therapy. Chirigos, M. A. (ed.). Cancer Treat. Rep. (in press) (1978).
Florentin, I., Kiger, N., Bruley-Rosset, M., Schulz, I. J., Mathé, G.: Effect of seven immunomodulators on different types of immune responses in mice. In: Human lymphocyte differentiation, its application to human cancer. Serrou, B., Rosenfeld, C. (eds.), Vol. 1. Amsterdam: Elsevier North-Holland (in press) (1978).
Hortobagyi, G. N., Gutterman, J. U., Richman, S. P., Hersh, E. M.: Pseudomonas aeruginosa vaccine: a phase I evaluation for cancer immunotherapy. Cancer Immunol. Immunother. (in press) (1978).
Martinez, J., Winternitz, F., Vindel, J.: Nouvelles synthèses et propriétés de la tuftsine. Eur. J. Med. Chem. (in press) (1978).
Mathé, G.: Cancer active immunotherapy, immunoprophylaxis and immunorestoration. Vol. 1. Heidelberg, New York: Springer 1976.
Mathé, G., Florentin, I., Bruley-Rosset, M., Hayat, M., Bourut, C.: Heat-killed pseudomonas aeruginosa as a systemic adjuvant in cancer immunotherapy. Biomedicine 27, 368 (1977).
Mathé, G., de Vassal, F., Gouveia, J., Simmler, M. C., Misset, J. L.: Comparison of the restoration effect of pseudomonas aeruginosa, BCG and poly I: poly C on cancer patients non responsive to recall antigen delayed hypersensitivity. Biomedicine 27, 328 (1977).
Mathé, G., Olsson, L., Florentin, I., Kiger, N.: Post-surgical systematic active immunotherapy: rational, experimental and clinical basis on non solid tumors. In: Adjuvant therapies and markers of post-surgical minimal residual disease I. Bonadonna, G., Mathé, G., Salmon, S. E. (eds.). RRCR Vol. 67, pp. 132-150. Berlin, Heidelberg, New York: Springer 1979.
Oettgen, H. F.: Effects of endotoxin and endotoxin-induced mediators on cancer and on the immune system. In: The role of nonspecific immunity in the prevention and treatment of cancer. Study Week of the Pontifical Academy of Sciences. Vatica City, (in press) (1978).
Orbach-Arbouys, S., Castes, M., Berardet, M.: Enhancement of immunological responses by methotrexate pretreatment as a result of an eventual elimination of suppressor cells. In: Experimental hematology today. Berlin, Heidelberg, New York: Springer (in press) (1978).
Patt, Y. Z., Hersh, E. M., Goldman, R., Washington, M.: Suppressor cells in cancer patients and possible effects of thymic hormone. In: Immune modulation and control of neoplasie by adjuvant therapy. Chirigos, M. A. (ed.). Cancer Treat. Rep. (in press) (1978).
Schulz, J. I., Florentin, I., Bourut, C., Bicker, O., Mathé, G.: Delayed-type hypersensitivity response and humoral antibody formation in mice treated. A new immunostimulant 2-2-cyanaziridinyl-(1)-2-2-carbamoyl aziridinyl-(1)-propane BM 12 531. I.R.S.C. Med. Sci. 6, 215 (1978).
Strelkauskas, A. J., Schauf, V., Wilson, B. S., Chess, L., Schlossman, J. F.: Isolation and characterization of naturally occuring subclasses of human peripheral blood T cells with regulatory functions. J. Immunol. 120, 1278 (1978).
Trainin, N., Small, M., Gabizon, A.: Thymic humoral factor (THF) as modulator of T cell differentiation involved in antitumor reactivity. In: Human lymphocyte differentiation, its application to human cancer. Serrou, B., Rosenfeld, C. (eds.), Vol. 1. Amsterdam: Elsevier North-Holland (in press) (1978).
Umezawa, H., Aoyagi, T., Suda, H., Hamada, M., Takeuchi, T.: Bestatin, a new amino-peptidase B inhibitor produced by actinomycetes. J. Antibiotics 29, 97 (1976).
Umezawa, H., Ishisuka, M., Aoyagi, T., Takeuchi, T.: Enhancement of delayed-type hypersensitivity by Bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase. J. Antibiotics 29, 857 (1976).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1979 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Mathé, G., Florentin, I., Schulz, J.I., Bruley-Rosset, M., Kiger, N. (1979). Third Generation of Systemic Adjuvants of Immunity: Experimental Basis for Adjuvant Combinations. In: Bonadonna, G., Mathé, G., Salmon, S.E. (eds) Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II. Recent Results in Cancer Research, vol 68. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81332-0_66
Download citation
DOI: https://doi.org/10.1007/978-3-642-81332-0_66
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81334-4
Online ISBN: 978-3-642-81332-0
eBook Packages: Springer Book Archive